Dishman Carbogen Amcis Limited (DCAL.NS)
INR 210.31
(1.37%)
INR 210.31
(1.37%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.9 Billion INR | -74.21% |
| 2022 | 19.01 Billion INR | 13.06% |
| 2021 | 16.81 Billion INR | 17.78% |
| 2020 | 14.27 Billion INR | -10.35% |
| 2019 | 15.92 Billion INR | -2.82% |
| 2018 | 16.39 Billion INR | 22.08% |
| 2017 | 13.42 Billion INR | -2.44% |
| 2016 | 13.76 Billion INR | 10.07% |
| 2015 | 12.5 Billion INR | 20.71% |
| 2014 | 10.35 Billion INR | 2.83% |
| 2013 | 10.07 Billion INR | 12.89% |
| 2012 | 8.92 Billion INR | 20.62% |
| 2011 | 7.39 Billion INR | 36.62% |
| 2010 | 5.41 Billion INR | -2.98% |
| 2009 | 5.57 Billion INR | -15.32% |
| 2008 | 6.58 Billion INR | 45.63% |
| 2007 | 4.52 Billion INR | 39.22% |
| 2006 | 3.25 Billion INR | 159.18% |
| 2005 | 1.25 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 696 Million INR | 4.19% |
| 2023 Q2 | 4.52 Billion INR | -19.25% |
| 2023 Q1 | 5.6 Billion INR | 27.53% |
| 2023 FY | 4.9 Billion INR | -74.21% |
| 2023 Q4 | 668 Million INR | -52.94% |
| 2023 Q3 | 1.41 Billion INR | -68.61% |
| 2022 FY | 19.01 Billion INR | 13.06% |
| 2022 Q1 | 4.48 Billion INR | 9.47% |
| 2022 Q2 | 4.52 Billion INR | 0.92% |
| 2022 Q4 | 4.39 Billion INR | -21.72% |
| 2022 Q3 | 5.6 Billion INR | 23.91% |
| 2021 Q4 | 4.09 Billion INR | -5.41% |
| 2021 FY | 16.81 Billion INR | 17.78% |
| 2021 Q2 | 4.16 Billion INR | -1.36% |
| 2021 Q1 | 4.22 Billion INR | 20.33% |
| 2021 Q3 | 4.33 Billion INR | 4.02% |
| 2020 FY | 14.27 Billion INR | -10.35% |
| 2020 Q4 | 3.5 Billion INR | -7.19% |
| 2020 Q3 | 3.78 Billion INR | 1.5% |
| 2020 Q2 | 3.72 Billion INR | 14.14% |
| 2020 Q1 | 3.26 Billion INR | -26.65% |
| 2019 Q1 | 3.71 Billion INR | -36.23% |
| 2019 FY | 15.92 Billion INR | -2.82% |
| 2019 Q2 | 3.87 Billion INR | 4.34% |
| 2019 Q4 | 4.44 Billion INR | 14.17% |
| 2019 Q3 | 3.89 Billion INR | 0.68% |
| 2018 Q3 | 3.55 Billion INR | -2.17% |
| 2018 Q2 | 3.63 Billion INR | 7.33% |
| 2018 Q1 | 3.38 Billion INR | -2.14% |
| 2018 Q4 | 5.81 Billion INR | 63.7% |
| 2018 FY | 16.39 Billion INR | 22.08% |
| 2017 Q4 | 3.45 Billion INR | 5.63% |
| 2017 FY | 13.42 Billion INR | -2.44% |
| 2017 Q3 | 3.27 Billion INR | -6.79% |
| 2017 Q2 | 3.51 Billion INR | 20.72% |
| 2017 Q1 | 2.91 Billion INR | -21.28% |
| 2016 Q1 | 3.11 Billion INR | 8.2% |
| 2016 Q2 | 3.35 Billion INR | 7.51% |
| 2016 Q4 | 3.69 Billion INR | 28.34% |
| 2016 Q3 | 2.88 Billion INR | -14.04% |
| 2016 FY | 13.76 Billion INR | 10.07% |
| 2015 Q3 | 2.98 Billion INR | 5.16% |
| 2015 Q4 | 2.88 Billion INR | -3.35% |
| 2015 FY | 12.5 Billion INR | 20.71% |
| 2015 Q1 | 3.17 Billion INR | 28.79% |
| 2015 Q2 | 2.83 Billion INR | -10.78% |
| 2014 Q4 | 2.46 Billion INR | -4.55% |
| 2014 Q3 | 2.58 Billion INR | -5.52% |
| 2014 Q1 | 2.57 Billion INR | -10.91% |
| 2014 Q2 | 2.73 Billion INR | 6.38% |
| 2014 FY | 10.35 Billion INR | 2.83% |
| 2013 Q4 | 2.88 Billion INR | 29.79% |
| 2013 Q3 | 2.22 Billion INR | -16.17% |
| 2013 Q2 | 2.65 Billion INR | 14.86% |
| 2013 Q1 | 2.3 Billion INR | -7.45% |
| 2013 FY | 10.07 Billion INR | 12.89% |
| 2012 Q3 | 2.08 Billion INR | 3.21% |
| 2012 Q4 | 2.49 Billion INR | 19.39% |
| 2012 Q1 | 2.31 Billion INR | -0.02% |
| 2012 FY | 8.92 Billion INR | 20.62% |
| 2012 Q2 | 2.02 Billion INR | -12.38% |
| 2011 Q4 | 2.31 Billion INR | 30.32% |
| 2011 Q3 | 1.77 Billion INR | 0.0% |
| 2011 FY | 7.39 Billion INR | 36.62% |
| 2010 FY | 5.41 Billion INR | -2.98% |
| 2009 FY | 5.57 Billion INR | -15.32% |
| 2008 FY | 6.58 Billion INR | 45.63% |
| 2007 FY | 4.52 Billion INR | 39.22% |
| 2006 FY | 3.25 Billion INR | 159.18% |
| 2005 FY | 1.25 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biocon Limited | 91.73 Billion INR | 94.654% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | -55.222% |
| Concord Biotech Limited | 7.56 Billion INR | 35.173% |
| Jubilant Ingrevia Limited | 9.16 Billion INR | 46.5% |
| Lyka Labs Limited | 145.95 Million INR | -3259.872% |
| Panacea Biotec Limited | 1.42 Billion INR | -243.476% |
| Piramal Pharma Limited | 24.47 Billion INR | 79.961% |
| SMS Lifesciences India Limited | 329.57 Million INR | -1387.912% |
| Supriya Lifescience Limited | 2.65 Billion INR | -84.923% |
| Syngene International Limited | 12.43 Billion INR | 60.574% |
| TAKE Solutions Limited | 183.42 Million INR | -2573.536% |
| Zota Health Care Limited | 332.52 Million INR | -1374.707% |